BioSpace News Archive

Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immunotherapeutics that restore anti-cancer immunity to the patient, today announced that Curtis Ruegg , Ph.D., President and CEO, will present a company overview at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020

Initial data from the Phase 1 dose escalation trial in 18 patients with advanced solid tumors shows AMV564 administered subcutaneously was well tolerated, with no dose-limiting toxicities

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa , Chief Executive Officer of Relmada, will present a corporate overview at the Jefferies 2020 Virtual Healthcare Conference, being held June 2-4, 2020

SEngine Precision Medicine , a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on patient-derived tumor-based organoids, today presented data on the predictive value of the PARIS® Test in its poster, “Predictive value of a CLIA-approved organoid based drug sensitivity test” (poster board #360), during the 2020 ASCO Virtual Meeting being held May 29 – 31, 2020. The PARIS® Test is CLIA certified

Week 9 (May 17 to 19) results from Sermo’s COVID-19 Real Time Barometer with 4,193 physicians reveal COVID-19 treatment patterns among frontline physicians. In total, Sermo’s Barometer study includes over 49,000 survey interviews in 31 countries, including the United States, Canada, United Kingdom, France, Brazil, Russia, China, Japan and Australia

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz, president and chief executive officer at Mirum will present at the virtual Jefferies 2020 Healthcare Conference on June 2, 2020 at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time. A live audio webcast and archi

OrPro Therapeutics announced today that it is expanding its patented technology platform for treatment of acute and chronic airway diseases, including cystic fibrosis (CF), to address the immediate threat posed by COVID-19.

Bold Therapeutics, a clinical-stage biopharmaceutical company, announced it has executed an option agreement with Hana Pharm Co. Ltd. for exclusive rights to BOLD-100 in South Korea.

The number of shares and votes in Orexo AB has changed as a result of the cancellation of 842,971 class C shares, which was resolved at the Annual General Meeting held on April 16, 2020.

Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved ZILXI™ (minocycline) topical foam, 1.5%, for the treatment of inflammatory lesions of rosacea in adults.